Leerink Partners Resumes GW Pharma (GWPH) at Outperform
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Leerink Partners resumes coverage on GW Pharma (NASDAQ: GWPH) with a Outperform rating and a price target of $162.00.
Analyst Paul Matteis commented, "We are highly positive on the potential uptake trajectory of Epidiolex, the approval for which appears mostly de-risked after 3 successful ph III trials in Dravet Syndrome (DS) & Lennox Gastaut (LGS). As GW approaches the next stage of its life-cycle - where ahead of approval, investors will wonder if GW will sell or launch independently - we believe either path offers an avenue to stock upside. While nascent commercial biotechs tend to pioneer relatively slow product rollouts, we see multiple points of optimism regarding a GW-led global launch: (1) strong clinical profile of, and "hype" surrounding Epidiolex - >1,000 patients on drug today; (2) significant level of unmet medical need in DS, LGS & refractory seizures; (3) small subset of core prescribers - just ~4-5k epileptologists in the US; (4) the experience of CCO Julian Gangoli, who previously ran commercial for Allergan North America."
Shares of GW Pharma closed at $132.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
- UPDATE: Oppenheimer Downgrades Williams-Sonoma (WSM) to Perform
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!